Research article
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
-
* Corresponding author: Sandra E Dunn sedunn@interchange.ubc.ca
1 Laboratory for Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, W. 28th Avenue, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada
2 Genetic Pathology Evaluation Center, Jack Bell Research Center, Oak Street, Vancouver, BC, V6H 3Z6, Canada
3 Division of Medical Oncology, British Columbia Cancer Agency, West 10th Avenue, Vancouver, BC, V5Z 1L3 Canada
4 Department of Pathology and Laboratory, West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada
5 Division of Medical Oncology, Jewish General Hospital – Lady Davis Institute, Côte Ste Catherine Road, Montreal, Quebec H3T 1E2, Canada
Breast Cancer Research 2008, 10:R86 doi:10.1186/bcr2156
Published: 16 October 2008Additional files
Additional file 1:
This file shows that YB-1 is strongly associated with poor survival in node-positive and node-negative breast cancers. In node-negative tumors YB-1 was expressed in 33% (572/1,730) of the cases, in which it was strongly associated with reduced BCSS. Similarly, it was expressed in 37% (506/1356) of node-positive breast cancer cases. In these cases YB-1 was also positively associated with reduced BCSS.
Format: JPEG Size: 241KB Download file
Additional file 2:
This file shows correlations between YB-1 and clinicopathological features of breast cancer. Patients who had tumors expressing YB-1 were younger and tended to have tumors that lacked the ER. There was a positive correlation with increasing tumor grade. Often, tumors that exhibited amplifications in HER-2 also expressed high levels of YB-1. Conversely, YB-1 was not associated with nodal status and weakly related to tumor size.
Format: JPEG Size: 254KB Download file
Additional file 3:
This file shows that YB-1 is significantly associated with relapse, independent of the type of breast cancer. The expression of YB-1 was associated with shorter RFS (HR = 1.284; P = 0.008), independent of breast cancer subtype defined by hormone receptor and HER-2 status, based on a Cox regression analysis.
Format: JPEG Size: 470KB Download file
Additional file 4:
This file shows that the prognostic significance of YB-1 is associated with reduced BCSS (HR = 1.46, P = 6.74 × 10-7), independent of tumor subtype.
Format: JPEG Size: 478KB Download file
Additional file 5:
This file shows a Cox regression model for patients who were treated with surgical resection and no chemotherapy. Nodal status, tumor size, and YB-1 expression were associated with reduced BCSS. YB-1 was better than HER-2 or ER for predicting BCSS.
Format: JPEG Size: 425KB Download file
Additional file 6:
This file shows a Cox regression analysis for ER-positive patients treated with tamoxifen for 5 years. YB-1 was independently associated with an increased risk for reduced BCSS (HR = 1.703, P = 0.022). YB-1 complemented the significance found in node status, tumor size (greater than 2 cm only), and grade. Patient age, small tumors (<2 cm), and HER-2 expression were not independently associated with reduced BCSS.
Format: JPEG Size: 429KB Download file
